Where Will Gilead Sciences Be in 1 Year?
Gilead Sciences (NASDAQ: GILD) has become a rather peculiar stock this year. On the one hand, the company has many investors excited about its coronavirus treatment, Veklury. On the other, its stock has fallen about 5% year to date, far underperforming the S&P 500's 17% total gain during the same period.
The discrepancy between expectations and reality has left many wondering if the stock will end up higher in 2021 or continue to lag behind major indexes. From its financial updates, it seems like its shares are definitely undervalued, but may continue to trade at the same levels in the near future. Let's find out why this is the case.
Image source: Getty Images.
Source Fool.com
